OR WAIT null SECS
Care Access Research has announced that it is collaborating with Eli Lilly and Company. Care Access Research is helping Lilly manage the system of decentralized, mobile clinical COVID-19 trials as part of the partnership. The BLAZE-2 phase III trial of Lilly's monoclonal antibody (mAb) LY-CoV555, has been initiated nationwide at nursing homes, a community proven to be especially vulnerable to SARS-COV2, the virus which causes COVID-19.
The trial is truly mobile with the deployment of traveling teams of trucks, RVs and personnel on the road simultaneously. Unlike virtual trials, the mobile research teams are capable of providing complex in-person patient care, including infusions, and have access to a fully functioning lab fitted with centrifuges, lab kits, and medical supplies that will help thousands of long-term facility residents and staff participate in this pivotal clinical trial. This unique model is scalable and implements innovative software and processes that aims to accelerate clinical trials, by making it easy to reach over 2,000 participants in a matter of months.
“COVID-19 has had a devastating impact on nursing home residents. We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals. While it's not easy to conduct clinical trials in this setting, we're taking on the challenge in an effort to help those who need us the most,” said Daniel Skovronsky, M.D., PhD, Lilly's chief scientific officer and president of Lilly Research Laboratories.
Read the full release here.